Treatment of lymphoid neoplasias with interferon. I. Human fibroblastic beta-interferon in malignant gammapathies. Phase II trial

18 patients with malignant gammapathies (16 with myeloma and 2 with Waldenström's disease) were treated with human fibroblastic Interferon (beta IF). This was administered i.v. 6 X 10(6) units weekly (7 patients) or 3 X 10(6) units twice weekly (11 patients). during at least 3 months if tolerat...

Full description

Saved in:
Bibliographic Details
Published inAnticancer research Vol. 2; no. 1-2; p. 63
Main Authors Misset, J L, Mathé, G, Gastiaburu, J, Goutner, A, Dorval, T, Gouveia, J, Hayat, M, Jasmin, C, Schwarzenberg, L, Machover, D, Ribaud, P, De Vassal, F, Horoszewicz, J S
Format Journal Article
LanguageEnglish
Published Greece 01.01.1982
Subjects
Aged
B-Lymphocytes - metabolism
Drug Evaluation
Female
Fibroblasts - metabolism
Humans
Interferons - administration & dosage
Interferons - adverse effects
Interferons - biosynthesis
Interferons - therapeutic use
Male
Middle Aged
Multiple Myeloma - therapy
Waldenstrom Macroglobulinemia - therapy
Online AccessGet more information

Cover

More Information
Summary:18 patients with malignant gammapathies (16 with myeloma and 2 with Waldenström's disease) were treated with human fibroblastic Interferon (beta IF). This was administered i.v. 6 X 10(6) units weekly (7 patients) or 3 X 10(6) units twice weekly (11 patients). during at least 3 months if tolerated. Treatment was discontinued because of side effects in three patients. Reduction of the M component, by at least 25% from the initial value, was obtained in 3 patients. In one case the disappearance of a urinary Bence Jones protein was observed. In 4 cases, there was a significant reduction of bone marrow infiltration by plasma cells. In 5 cases, major alleviation or disappearance of bone pain was observed. Duration of treatment seemed to be an important factor for activity. Immune monitoring with currently available tests, mainly natural cytoxicity, yielded no correlation with therapeutic effect in these patients. This preliminary study demonstrates the effect of fibroblastic Interferon in myeloma. However, further studies are necessary to determine the population of patients most likely to benefit from treatment, the best modalities, possible special indications, dose schedules and duration of treatment. As it is not myelosuppressive it could be indicated in the frequent situation of advanced myeloma with bone marrow failure, contra-indicating combination chemotherapy.
ISSN:0250-7005